The taccalonolides: Microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms

Cancer Research

Volumn 68, Issue 21, 2008, Pages 8881-8888

  Risinger, April L ^a   Jackson, Evelyn M ^a   Polin, Lisa A ^b   Helms, Gregory L ^c   LeBoeuf, Desiree A ^a   Joe, Patrick A ^a   Hopper Borge, Elizabeth ^d   Ludueña, Richard F ^a   Kruh, Gary D ^d   Mooberry, Susan L ^a,e  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WASHINGTON STATE UNIVERSITY   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; ANTINEOPLASTIC AGENT; BETA TUBULIN; DOCETAXEL; DOXORUBICIN; EPOTHILONE B; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 7; PACLITAXEL; PLANT EXTRACT; TACCA CHANTRIERI EXTRACT; TACCALONOLIDE A; TACCALONOLIDE B; TACCALONOLIDE E; TACCALONOLIDE N; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VINBLASTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL; CANCER RESISTANCE; CELL ISOLATION; CELL LINE; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG ISOLATION; DRUG RESISTANCE; DRUG SENSITIVITY; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO CULTURE; MALE; MICROTUBULE; MICROTUBULE ASSEMBLY; MOUSE; NONHUMAN; PLANT; PRIORITY JOURNAL; PROTEIN EXPRESSION; R FACTOR; TACCA CHANTRIERI;

ANIMALS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; MICE; MICE, INBRED C3H; MICROTUBULES; STEROIDS; TAXOIDS;

EID: 55349087539     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2037     Document Type: Article

References (43)

1. Rowinsky EK, Tolcher AW. Antimicrotubule agents. In: DeVita VTJ, Hellman S, Rosenberg SA, editors. Cancer principles and practice of oncology. Philadelphia (PA): Lippincott, Williams and Wilkins; 2001. p. 431-47.
2. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65.
3. Jordan MA, Kamath K. How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets 2007;7:730-42.
4. Chu Q, Vincent M, Logan D, Mackay J, Evans W. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline. Lung Cancer 2005;50:355-74.
5. Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 2005;6:229-39.
6. Fojo T, Menefee M. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Ann Oncol 2007;18:3-8.
7. Conlin A, Fornier M, Hudis C, Kar S, Kirkpatrick P. Ixabepilone. Nat Rev Drug Discov 2007;6:953-54.
8. Mita A, Lockhart AC, Chen T-L, et al. A phase I pharmacokinetic (PK) trial of XAA296A (discodermolide) administered every 3 wks to adult patients with advance solid malignancies. J Clin Oncol 2004;22:2025.
9. Tinley TT, Randall-Hlubek DA, Leal RM, et al. Taccalonolides E and A: plant-derived steroids with microtubule-stabilizing activity. Cancer Res 2003;63:3211-20.
10. Buey RM, Barsoain I, Jackson E, et al. Microtubule interactions with chemically diverse stabilizing agents: thermodynamics of binding to the Taxol site predicts cytotoxicity. Chem Biol 2005;12:1269-79.
11. Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002;71:537-92.
12. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist 2003;8:411-24.
13. Rottenberg S, Nygren AOH, Pajic M, et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci U S A 2007;104:12117-22.
14. Borst P, Jonkers J, Rottenberg S. What makes tumors multidrug resistant? Cell Cycle 2007;6:2782-7.
15. Yeh JJ, Hsu WH, Wang JJ, Ho ST, Kao A. Predicting chemotherapy response to Taxol-based therapy in advanced non-small-cell lung cancer with P-glycoprotein expression. Respiration 2003;70:32-5.
16. Chiou J-F, Liang J-A, Hsu W-H, Wang J-J, Ho S-T, Kao A. Comparing the relationship of Taxol-based chemotherapy response with P-glycoprotein and lung resistance-related protein expression in non-small cell lung cancer. Lung 2003;181:267-73.
17. Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 1997;89:917-31.
18. Hopper E, Belinsky MG, Zeng H, Tosolini A, Testa JR, Kruh GD. Analysis of the structure and expression pattern of MRP7 (ABCC10), a new member of the MRP subfamily. Cancer Lett 2001;162:181-91.
19. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD. Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol 2003;63:351-8.
20. Hopper-Borge E, Chen ZS, Shchaveleva I, Belinsky MG, Kruh GD. Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res 2004;64:4927-30.
21. Dabrowska M, Sirotnak FM. Regulation of transcription of the human MRP7 gene. Characteristics of the basal promoter and identification of tumor-derived transcripts encoding additional 5′ end heterogeneity. Gene 2004;341:129-39.
22. Takayanagi S, Kataoka T, Ohara O, Oishi M, Kuo MT, Ishikawa T. Human ATP-binding cassette transporter ABCC10: expression profile and p53-dependent up-regulation. J Exp Ther Oncol 2004;4:239-46.
23. Oguri T, Ozasa H, Uemura T, et al. MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer. Mol Cancer Ther 2008;7:1150-5.
24. Seve P, Dumontet C. Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol 2008;9:168-75.
25. Panda D, Miller HP, Banerjee A, Ludueña RF, Wilson L. Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proc Natl Acad Sci U S A 1994;91:11358-62.
26. Lu Q, Ludueña RF. Removal of β III isotype enhances Taxol induced microtubule assembly. Cell Struct Funct 1993;18:173-82.
27. Kamath K, Wilson L, Cabral F, Jordan MA. βIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem 2005;280:12902-7.
28. Gan PP, Pasquier E, Kavallaris M. Class III β-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res 2007;67:9356-63.
29. Chen Z-L, Shen J-H, Gao Y-S. Some chemical reactions of taccalonolide A - a bitter substance from Tacca plantaginea. Heterocycles 1989;29:2103-8.
30. Sadava D, Coleman A, Kane SE. Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma cells. J Liposome Res 2002;12:301-9.
31. Joe PA, Banerjee A, Ludueña RF. The roles of Cys124 and Ser239 in the functional properties of human βIII tubulin. Cell Motil Cytoskeleton 2008;65:476-86. Epub 2008 Apr 24.
32. Boyd MR, Paull KD. Some practical considerations and applications of the National Cancer Institute in vitro anticancer discovery screen. Drug Dev Res 1995;34:91-109.
33. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-12.
34. Banerjee A, Roach MC, Trcka P, Ludueña RF. Preparation of a monoclonal antibody specific for the class IV isotype of β-tubulin. Purification and assembly of αβII, αβIII, and αβIV tubulin dimers from bovine brain. J Biol Chem 1992;267:5625-30.
35. Weiderhold KN, Randall-Hlubek DA, Polin LA, Hamel E, Mooberry SL. CB694, a novel antimitotic with antitumor activities. Int J Cancer 2006;118:1032-40.
36. Corbett T, Polin L, Roberts BJ, et al. Transplantable syngeneic rodent tumors: solid tumors in mice. In: Teicher BA, editor. Tumor models in cancer research. Totowa (NJ): Humana Press; 2002.
37. Schumacher G, Hoffmann J, Cramer T, et al. Antineoplastic activity of 2-methoxyestradiol in human pancreatic and gastric cancer cells with different multidrug-resistant phenotypes. J Gastroenterol Hepatol 2007;22:1469-73.
38. Hari M, Yang H, Zeng C, Canizales M, Cabral F. Expression of class III β-tubulin reduces microtubule assembly and confers resistance to Taxol. Cell Motil Cytoskeleton 2003;56:45-56.
39. Fellous A, Francon J, Lennon AM, Nunez J. Microtubule assembly in vitro. Purification of assembly-promoting factors. Eur J Biochem 1977;78:167-74.
40. Banerjee A, Roach MC, Wall KA, Lopata MA, Cleveland DW, Ludueña RF. A monoclonal antibody against the type II isotype of β-tubulin. Preparation of isotypically altered tubulin. J Biol Chem 1988;263:3029-34.
41. Ludueña R, Banerjee A. The isotypes of tubulin: distribution and functional significance. In: Fojo T, editor. Microtubules. Totowa (NJ): Humana Press; 2005.
42. Furuta E, Pai SK, Zhan R, et al. Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1. Cancer Res 2008;68:1003-11.
43. Raspaglio G, Filippetti F, Prislei S, et al. Hypoxia induces class III β-tubulin gene expression by HIF-1α binding to its 3′ flanking region. Gene 2008;409:100-8.